Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their meta-analysis, Dr Bongartz and colleagues1 assessed the risks of infections and malignancies associated with the use of tumor necrosis factor α (TNF-α) antibody therapies in randomized controlled trials of patients with rheumatoid arthritis (RA). Because each original study had few events, answering this question requires pooling the findings of many trials, each of which has limited power to examine adverse event rates.
Costenbader KH, Glass R, Cui J, Shadick N. Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis. JAMA. 2006;296(18):2201-2204. doi:10.1001/jama.296.18.2201-a